Bulleted statements {#Sec1}
===================

what's already known about this topic? Non-invasive prenatal testing (NIPT) for fetal RhD from maternal plasma may enable targeted anti-D prophylaxis for RhD-negative women carrying an RhD-positive fetus.what does this study add? NIPT of fetal RhD shows high sensitivity and specificity and is equivalent to conventional postnatal testing using a blood sample of the newborn.

Background {#Sec2}
==========

During pregnancy, a Rhesus D (RhD)-negative woman may develop antibodies if her fetus is RhD-positive. These maternal allo-antibodies directed against fetal red cell surface antigens that the mother herself lacks can lead to hemolytic disease of the fetus and newborn (HDFN) \[[@CR1]\]. Anti-D immunoglobulin (anti-D) administration was introduced in the early 1970s to reduce the incidence of alloimmunization (sensitization) of pregnant women to the D antigen and subsequently the incidence of HDFN, which has since decreased dramatically \[[@CR2]\]. In many countries, the current policy is to administer anti-D to non-sensitized RhD-negative pregnant women in the 28th week of gestation \[[@CR3]\]. After birth, the cord blood is phenotyped and postnatal anti-D prophylaxis is offered only if the newborn is RhD-positive.

In a Cochrane review of 6 randomized controlled trials (RCTs), postnatal anti-D prophylaxis was shown to be effective in reducing the incidence of sensitization 6 months after birth and in a subsequent pregnancy \[[@CR2]\]; the benefits were seen when anti-D was given within 72 h of birth, with higher doses being more effective than lower ones. However, postnatal prophylaxis does not prevent antenatal sensitization \[[@CR4]\]. The current policy of universal antenatal anti-D administration leads to approximately 50,000 RhD-negative pregnant women per year in Germany receiving anti-D prophylaxis even though they are carrying an RhD-negative fetus \[[@CR5]\].

Non-invasive prenatal testing (NIPT) for fetal RhD from maternal plasma may enable anti-D prophylaxis to be withheld from RhD-negative women carrying an RhD-negative fetus. As early as 1998, Lo et al. \[[@CR6]\] described the presence of fetal DNA in maternal plasma and the possibility of non-invasive determination of the fetal RhD status. These findings enable non-invasive, risk-free antenatal testing, which is mostly performed using the real-time polymerase chain reaction (PCR).

The aim of the current article was to systematically review the evidence on the benefit of NIPT for fetal RhD status in RhD-negative pregnant women and subsequent targeted anti-D prophylaxis. The focus of the assessment was on patient-relevant outcomes.

Methods {#Sec3}
=======

Protocol and methodological approach {#Sec4}
------------------------------------

IQWiG's responsibilities and general methods are described in its methods paper \[[@CR7]\]. The methods for the present assessment were defined a priori and published in a German-language protocol on the website of the German Institute for Quality and Efficiency in Health Care (IQWiG) \[[@CR8]\]. The full German-language report including the original literature search \[[@CR9]\], as well as an English-language extract \[[@CR10]\], are also available on the website. The report is currently being used to inform a reimbursement decision on future RhD testing in Germany, thus potentially affecting about 750.000 pregnant women per year.

An update search was conducted for the current article, which was written according to the PRISMA statement \[[@CR11]\] (see Additional file [1](#MOESM1){ref-type="media"}).

Eligibility criteria {#Sec5}
--------------------

The target population comprised non-sensitized RhD-negative pregnant women investigated in controlled intervention studies of the diagnostic-therapeutic chain. The test intervention was NIPT for fetal RhD, with subsequent administration or withholding of anti-D prophylaxis, depending on the test result. The control intervention was conventional anti-D prophylaxis for all non-sensitized RhD-negative pregnant women using the anti-D dose approved in Germany. The patient-relevant outcomes investigated included rates of mortality, HDFN and adverse events as well as health-related quality of life (if meaningful, referring to both maternal and fetal or pediatric outcomes). Sensitization rates were investigated as a surrogate outcome for HDFN.

If the kind of direct evidence described above was not available, we planned to apply a linked evidence approach \[[@CR12]\].

We considered the following evidence and study types:

Either direct evidence from RCTs of the diagnostic-therapeutic chain (if not available, prospective intervention studies were also considered). Or, if no direct evidence was available, linked evidence \[[@CR12]\] from studies on diagnostic accuracy, together with controlled intervention studies investigating the benefit (prevention of sensitization) and harm (adverse events) of antenatal anti-D prophylaxis. The detailed eligibility criteria are presented in Table [1](#Tab1){ref-type="table"}. Table 1Eligibility criteriaDirect evidenceLinked evidenceintervention studiesdiagnostic accuracy studyintervention studiesPopulation• RhD-negative pregnant women without sensitization• RhD-negative pregnant women without sensitization• RhD-negative pregnant women without sensitizationStudy intervention• non-invasive prenatal RhD-testing of the fetus and omission of antenatal anti-D prophylaxis in the case of an RhD- negative fetus• non-invasive prenatal RhD-testing of the fetus• administration of anti-D prophylaxisControl intervention• anti-D prophylaxis for all RhD-negative pregnant women• postnatal RhD-testing of the newborn• no antenatal administration of anti-D prophylaxisBenefitsHarmsPatient-relevant outcomes/diagnostic accuracy measures• mortality• test accuracy (sensitivity, specificity, false-negative rate, false-positive rate)• mortality• mortality• HDFN (surrogate outcome: sensitization)• HDFN (surrogate outcome: sensitization)• adverse events• adverse events• health-related quality of life• health-related quality of life• health-related quality of lifeStudy type• RCTs• prospective cohort studies• RCTs• RCTs• prospective, non-randomized controlled intervention studies• prospective, non-randomized controlled intervention studies• prospective, non-randomized controlled intervention studies• cohort studies (also retrospective or with historical controls)HDFN: hemolytic disease of the fetus and newborn

Search strategy and study selection {#Sec6}
-----------------------------------

We searched for relevant primary studies and secondary publications (systematic reviews and HTA reports) in MEDLINE (1946 to October 2019) and EMBASE (1974 to October 2019) via Ovid as well as in the Cochrane Central Register of Controlled Trials (October 2019). The Cochrane Database of Systematic Reviews (Cochrane Reviews), the Database of Abstracts of Reviews of Effects (Other Reviews), and the Health Technology Assessment Database (Technology Assessments) were searched for relevant secondary publications. In addition, we screened web-based trial registries ([ClinicalTrials.gov](http://clinicaltrials.gov), International Clinical Trials Registry Platform Search Portal, and the EU Clinical Trials Register). The search strategy, which was developed by one information specialist and checked by another, is presented in Additional file [2](#MOESM2){ref-type="media"}. We also screened the websites of the European Medicines Agency and the US Food and Drug Administration.

Two reviewers independently screened titles and abstracts of the citations retrieved to identify potentially eligible primary and secondary publications. The full texts of these articles were obtained and independently evaluated by the same two reviewers applying the full set of inclusion and exclusion criteria. Disagreements were resolved by consensus. Study selection was performed in IQWiG's internal web-based trial selection database (webTSDB) \[[@CR13]\]. Endnote X9 was used for citation management.

Data extraction {#Sec7}
---------------

The individual steps of the data extraction and risk-of-bias assessment procedures were always conducted by one person and checked by another; disagreements were resolved by consensus. Details of the studies were extracted using standardized tables developed and routinely used by IQWiG. Depending on the study question (comparison of interventions or evaluation of diagnostic accuracy) we extracted information on study design, sample size, patient-relevant outcomes or diagnostic accuracy, location and period during which the study was conducted, dropout rate, gestational age, treatment regimen and control treatment or index test and reference standard, as well as risk-of-bias items (see below).

Assessment of risk of bias {#Sec8}
--------------------------

We assessed the risk of bias for individual studies, as well as for each outcome, and rated these risks as "high" or "low".

For controlled intervention studies, the risk of bias was assessed by determining the adequacy of the following quality criteria, which closely follow the criteria of the Cochrane risk-of-bias tool \[[@CR14]\]): generation of random allocation sequence or whether both treatment groups were studied in parallel, allocation concealment or comparability of groups, blinding of participants and investigators, as well as selective outcome reporting. If the risk of bias on the study level was rated as "high", the risk of bias on the outcome level was also generally rated as "high". The risk of bias for each outcome was assessed by determining the adequacy of the following quality criteria: blinding of outcome assessors, application of the intention-to-treat (ITT) principle, and selective outcome reporting.

For studies on diagnostic accuracy, the risk of bias was assessed by determining the adequacy of the following quality criteria following QUADAS-2 \[[@CR15]\]: patient selection, index test, reference standard, as well as flow and timing. Concerns about applicability were assessed by determining the adequacy of the following quality criteria: patient selection, index test and reference standard.

The risk of bias determines the confidence in the conclusions drawn from the study data and can be used to explore possible reasons for heterogeneity if the studies differ in their risk of bias.

Data analysis {#Sec23}
-------------

For the statistical analysis of controlled intervention studies, we used the results from the ITT analysis. We reported the treatment effects as odds ratios (ORs), including 95% confidence intervals (CIs), for binary outcomes. We conducted a random effects meta-analysis of intervention studies using the Knapp-Hartung method \[[@CR16]\] as well as sensitivity analyses using the Mantel-Haenszel method and a Beta-binomial model. No subgroup analyses were conducted.

Separate meta-analyses were performed to pool the results of diagnostic accuracy studies. Sensitivities and specificities were summarized in a bivariate meta-analysis. Model parameters were estimated by means of a generalized linear mixed model. No sensitivity or subgroup analyses were conducted.

All calculations were performed with the statistical software SAS.

Results {#Sec9}
=======

Literature search (see Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"} for flowchart) {#Sec10}
-----------------------------------------------------------------------------------------------------

Overall, 2237 studies were screened. No studies of the diagnostic-therapeutic chain were identified. 70 studies on diagnostic accuracy including approximately 66,000 participants were identified (all in bibliographic databases), of which the 12 largest (including over 90% of the total study population) were included in the analysis \[[@CR5], [@CR17]--[@CR28]\]. Two controlled intervention studies investigating the benefit (prevention of sensitization) of antenatal anti-D prophylaxis were identified (in bibliographic databases). However, they used a low and non-approved dose for anti-D prophylaxis \[[@CR29], [@CR30]\]. The results of these off-label studies are described below. No studies investigating harm (adverse events) from anti-D prophylaxis were identified. Fig. 1Flowchart of study selection for direct trial evidence and linked evidence (diagnostic accuracy studies) Fig. 2Flowchart of study selection for linked evidence (controlled intervention studies -- benefit and harm of anti-D prophylaxis)

Study characteristics {#Sec11}
---------------------

Table [2](#Tab2){ref-type="table"} presents the main characteristics of the 12 largest diagnostic accuracy studies and the two off-label studies on anti-D prophylaxis. Table 2Study characteristicsStudyStudy designParticipants (intervention/control)Treatment/index testPatient-relevant outcomes/ reference testLocation/recruitment periodWeeks' gestation Median \[min; max\]Drop-out (intervention/control)Huchet 1987 \[[@CR29]\]prospective intervention study1969 (927/955) with RhD-positive newborns: (599/590)100 μg anti-D immunoglobulin, one dose at 26 to 29 and one at 32--36 weeks' gestationsensitization23 hospitals in the Paris region 01/1983--06/1984Not statedLee 1995 \[[@CR30]\]RCT2541 (1268/1273) with RhD-positive newborns: (513/595)250 IU anti-D immunoglobulin at 28 and 34 weeks' gestationsensitizationMulti-center study in UK Not stated642 (362/280)De Haas 2016 \[[@CR17]\]prospective cohort study32,222cff-DNA*RHD* Exons 5 and 7serologic cord blood testingNetherlands (national screening program) 07/2011--10/2012Mean in weeks + days \[SD\] 27 + 6 \[0 + 6\] \[min; max\] \[27; 29\]6433Clausen 2014 \[[@CR18]\]prospective cohort study14,547cff-DNA*RHD* Exons 5, 7 or 10serologic cord blood testingDenmark (national screening program) 01/2010 for 2 years25 \[n. a.\]1879Haimila 2017 \[[@CR19]\]prospective cohort study10,814cff-DNA*RHD* Exons 5 and 7serologic cord blood testing / heel stickFinland (national screening program) 02/2014--01/2016n. a. \[24; 26\]0Wikman 2012 \[[@CR20]\]prospective cohort study4118cff-DNA*RHD* Exon 4serologic cord blood testing / blood sample of newbornSweden 09/2009--05/201110 \[3; 40\]466Chitty 2014 \[[@CR21]\]prospective cohort study3039cff-DNA*RHD* Exons 5 and 7serologic cord blood testingEngland 2009--201219 \[5; 35\]781Finning 2008 \[[@CR22]\]prospective cohort study1997cff-DNA*RHD* Exons 5 and 7serologic cord blood testingEngland/not stated28 \[8; 38\]128Müller 2008 \[[@CR5]\]prospective cohort study1113cff-DNA*RHD* Exons 5 and 7serologic cord blood testingGermany 2006 -- not stated25 \[6; 32\]91Macher 2012 \[[@CR23]\]prospective cohort study1012cff-DNA*RHD* Exons 5 and 7serologic cord blood testingSpain 2010n.a. \[10; 28\]0Hyland 2017 \[[@CR24]\]prospective cohort study665cff-DNARHD Exon 5 and 10serologic cord blood testingAustralia Not stated19.3 \[9; 37\]66Akolekar 2011 \[[@CR26]\]prospective cohort study591cff-DNA*RHD* Exons 5 and 7serologic cord blood testingUK Not stated12,4 \[11; 14\]5Minon 2008 \[[@CR27]\]prospective cohort study563cff-DNA*RHD* Exons 4, 5 and 10serologic cord blood testingBelgium 11/2002--12/200617,5 \[10; 38\]Not statedSoothill 2015 \[[@CR28]\]prospective cohort study529cff-DNA*RHD* Exons 5 and 7serologic cord blood testingEngland 04--09/2013Not stated30*cff* cell-free fetal, *n.a* not available, *RHD* rhesus factor, *SD* standard deviation

Risk of bias {#Sec12}
------------

Both off-label studies on anti-D prophylaxis showed a high risk of bias on the study and outcome level, for example, because of unclear information on the blinding of patients and investigators and/or an inappropriate ITT analysis. In 11 of the 12 diagnostic accuracy studies, the risk of bias was high in the total score (Table [3](#Tab3){ref-type="table"}). However, the pooled estimate of all studies were similar to the results of the study with the low risk of bias. Table 3Risk of bias of included studies (QUADAS 2) and concerns regarding applicabilityStudyPatient selectionIndex testReference standardFlow and timingApplicability concerns - totalDe Haas 2016lowunclearlowhighlowClausen 2014lowunclearunclearhighlowHaimila 2017lowunclearunclearlowlowWikman 2012lowunclearunclearhighlowChitty 2014unclearlowunclearhighlowFinning 2008unclearunclearlowlowlowMüller 2008lowunclearunclearlowlowMacher 2012lowunclearunclearlowlowHyland 2017lowunclearunclearlowlowAkolekar 2011unclearunclearunclearlowlowMinon 2008lowunclearunclearlowlowSoothill 2015lowlowlowlowlow

Effects of antenatal anti-D prophylaxis {#Sec13}
---------------------------------------

The meta-analysis of the results of the two off-label studies (Additional file [3](#MOESM3){ref-type="media"}) showed no significant differences in sensitization at the time of delivery (OR 0.33, 95% CI \[0; 123,851\], number of participants = 2297, number of studies = 2, I^2^ = 51%). The CI is very wide and the effect could not be estimated with adequate precision. We therefore conducted different sensitivity analyses with 2 different meta-analysis methods, the Mantel-Haenszel (MH) method and the beta-binomial model (BBM). Both led to more precise estimates (MH: 0.37 \[0.13; 1.06\], number of participants = 2297, number of studies = 2, I^2^ = 51%; BBM 0.30 \[0.07; 1.26\], number of participants = 2297, number of studies = 2), but neither showed a significant difference between the test and control groups.

Diagnostic accuracy {#Sec14}
-------------------

Sensitivities and specificities from the 12 studies are described comparatively in Table [4](#Tab4){ref-type="table"}. The bivariate meta-analysis showed high values for both measures of diagnostic accuracy of NIPT in RhD-negative pregnant women (sensitivity: 99.9% (95% CI \[99.5%; 100%\]; specificity: 99.2% (95% CI \[98.5%; 99.5%\], number of participants = 60,011, number of studies = 12). Two of the studies \[[@CR5], [@CR17]\] assessed discordant results of ante- and postnatal tests by genetic testing. They found that the postnatal test also produced a few incorrect test results (about 35 false-negative results out of 27,000 tests due to RhD variants or confusion of the samples), indicating that both tests can be regarded as equivalent. Table 4Diagnostic accuracy resultsStudynTPFNFPTNInconclusive results (%)^a,\ b^Sensitivity in % \[95% CI\]^b^Specificity in % \[95% CI\]^b^De Haas 201625,78915,816922597390 (0)^c^99.9 \[99.9; 100\]97.7 \[97.4; 98.0\]Clausen 201412,668763611414706274 (2.2)99.9 \[99.7; 99.9\]99.1 \[98.8; 99.4\]Haimila 201710,814708017364086 (0.80)100 \[99.9; 100\]99.8 \[99.6; 99.9\]Wikman 2012365222365515133115^b^ (0.4)97.6 \[96.9; 98.2\]98.9 \[98.2; 99.4\]Chitty 2014956^d^5351434175 (7.8)99.8 \[99.0; 100\]98.8 \[97.1; 99.7\]2288^e^256319181920393 (17.2)99.3 \[98.9; 99.6\]99.1 \[98.5; 99.4\]Finning 20081869111831467064 (3.4)99.7 \[99.2; 99.9\]98.0 \[96.6; 98.9\]Müller 20081022 "Spin column"^f^660^b^2^b^3^b^357^b^0 (0)^b^99.7 \[98.9; 100\]99.2 \[97.6; 99.8\] "Magnetic tips"^f^661^b^1^b^7^b^353^b^0 (0)^b^99.8 \[99.2; 100\]98.1 \[96.0; 99.2\]Macher 20121012619073860 (0)100 \[99.4; 100\]98.2 \[96.4; 99.3\]Hyland 2017599370012262 (0.3)^b^100 \[99.0; 100\]99.6 \[97.6; 100\]Akolekar 20115863326016484 (14.3)98.2 \[96.2; 99.3\]100 \[97.8; 100\]Minon 2008545360001850 (0)100 \[99.0; 100\]100 \[98.0; 100\]Soothill 20154992670117061^g^ (12.2)100 \[98.6; 100\]99.4 \[96.8; 100\]pooled estimate^h^99.9 \[99.5; 100\]99.2 \[98.5; 99.5\]a: Proportion of study participants with inconclusive resultsb: IQWiG's own calculationc: 0.21% of samples were inconclusive (women with RhD variants). In this study these samples were categorized by the positive samplesd: Results of the largest cohort of this study (11 to 13 weeks' gestation). These results are included in the pooled effecte: Summarized data for 2288 evaluated women with a total of 4913 data sets including up to 4 measurement points (multiple measurements). The number of blood samples is therefore shown heref: "Spin column" and "magnetic tips" are two different methods for the extraction of cff-DNA from plasma samples. The patients with samples extracted by the spin column method are included in the pooled effectg: Treated like positive samplesh: Generalized linear model to take into account the dependency between sensitivity and specificitycff: cell-free fetal; FN: false negative; FP: false positive; CI: confidence interval; n: number of evaluated participants; RHD: rhesus factor; TN: true negative; TP: true positive

Discussion {#Sec15}
==========

The current review shows a lack of studies investigating patient-relevant outcomes after NIPT for fetal RhD status in RhD-negative pregnant women and subsequent targeted anti-D prophylaxis. The analysis of diagnostic accuracy studies shows that NIPT has a high sensitivity and specificity.

Comparison with the literature {#Sec16}
------------------------------

### Anti-D prophylaxis {#Sec17}

The Cochrane review by McBain 2015 \[[@CR4]\] included the same two off-label studies on antenatal anti-D prophylaxis described in our review \[[@CR29], [@CR30]\]. In accordance with our findings, the authors stated that these two studies do not provide conclusive evidence that the use of anti-D during pregnancy shows a benefit in terms of incidence of Rhesus D sensitization.

A systematic review by Pilgrim 2009 \[[@CR31]\] contained 12 studies (including one of the off-label studies \[[@CR29]\] described in our review) with a high risk of bias, such as studies with historical controls, retrospective studies, and community intervention trials. They concluded that antenatal anti-D prophylaxis may reduce the incidence of sensitization. Furthermore, they noted that anti-D is associated with only minimal adverse effects.

In a systematic review by Turner 2012 \[[@CR32]\], a pooled OR of 0.31 (95% CI \[0.17; 0.56\]) was determined in an adjusted meta-analysis of 10 studies on the administration of antenatal anti-D prophylaxis and the incidence of sensitization. Among these were the two off-label studies described in our review and further studies with historical control groups. The authors concluded that there was strong evidence of the effectiveness of routine antenatal anti-D prophylaxis for prevention of sensitization.

### Diagnostic accuracy {#Sec18}

We identified 70 relevant studies on diagnostic accuracy, of which 58 included only a comparatively small number of participants (2 to 467). We therefore restricted our sample to the 12 largest studies, which comprised over 90% of the overall study population. A sufficiently accurate determination of the diagnostic accuracy of NIPT for fetal RhD was thus possible, showing high sensitivity and specificity.

Mackie 2017 \[[@CR33]\] included 30 studies and found a sensitivity of 99.3% (95% CI \[98.2, 99.7%\]) and a specificity of 98.4% (95% CI \[96.4, 99.3%\]). These results are comparable to our findings, despite a differing study pool (only 2 of the 30 studies were included in our review).

A British National Institute for Health and Care Excellence (NICE) report from 2016 \[[@CR34], [@CR35]\] on diagnostic accuracy included eight studies exclusively using "high throughput" NIPT (six of these studies were included in our review). The corresponding HTA report \[[@CR36]\] found that after 11 weeks of pregnancy only 1% of the samples showed an incorrect test result (almost all false-positive) and approximately 7% of the samples showed an inconclusive result. A pooled rate of false-negative results of 0.34% \[95% CI \[0.15%; 0.76%)\] was reported, which is comparable to the sensitivity determined in our review (99.9% \[95% CI \[99.5%; 100%\]). According to NICE, if antenatal anti-D prophylaxis was administered only to RhD-negative pregnant women with RhD-positive fetuses, this would result in potential cost savings between £296,000 and £409,000 per 100,000 pregnancies \[[@CR36], [@CR37]\]. NICE has issued a positive recommendation for NIPT \[[@CR38]\].

A French Haute Autorité de Santé (HAS) report on diagnostic accuracy from 2011 \[[@CR39], [@CR40]\] is based on 31 studies, which were not pooled in a meta-analysis. Despite the differing study pools (only two studies were included in our review), their results are comparable: the majority of the studies included (22 of 31) reported a sensitivity and specificity of over 95%. HAS concluded that the expected benefit of NIPT was sufficient to justify reimbursement by the health insurance funds, and it is now being reimbursed in France. They recommend applying the test between the 11th and 28th week of pregnancy.

Limitations {#Sec19}
-----------

The meta-analysis of diagnostic accuracy was limited by fact that the true fetal RhD status could not be determined by genetic testing in the primary studies. Only two studies resolved discrepancies between the ante- and postnatal test. As postnatal testing can also be incorrect, using postnatal test results as the reference standard might underestimate the true accuracy of the prenatal test. An additional limitation of the present review was the restriction of analyses to only the largest primary studies. However, the inclusion of all studies, regardless of sample size, would probably not have altered the main findings. Furthermore, the non-publication of negative findings is more common in smaller studies \[[@CR41]\], so focusing on larger studies reduces bias.

Ethical aspects {#Sec20}
---------------

With the implementation of NIPT for fetal RhD status, almost 40% of antenatal anti-D administrations could be saved per year in Germany \[[@CR5]\]. Important aspects are not only the costs, but also ethical issues concerning the acquisition of anti-D: male donors are sensitized with a blood product to produce the vaccine and the number of donors worldwide is limited; most countries rely on imports.

Conclusion {#Sec21}
==========

In summary, NIPT for fetal RhD status shows high sensitivity and specificity and is equivalent to conventional postnatal testing using a blood sample of the newborn, which also produces a few incorrect test results. Some countries (e.g. Denmark and Netherlands) have already implemented NIPT and have abolished postnatal testing. However, as studies investigating the effects of NIPT on patient-relevant outcomes are still lacking, before its widespread implementation as the only test to determine RhD status, we recommend evaluating the benefit of NIPT in the respective health care settings.
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BBM

:   beta-binomial model

CI

:   Confidence interval

DNA
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:   Haute Autorité de Santé

HDFN

:   Hemolytic disease of the fetus and newborn

HTA

:   Health Technology Assessment

IQWiG

:   Institute for Quality and Efficiency in Health Care

ITT

:   Intention-to-treat

MH

:   Mantel-Haenszel

NICE

:   National Institute for Health and Care Excellence

NIPT

:   Non-invasive prenatal testing

OR

:   Odds ratio

PCR

:   Polymerase chain reaction

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

QUADAS-2

:   Quality Assessment of Diagnostic Accuracy Studies 2

RCT

:   Randomized controlled trial

RhD

:   Rhesus D

webTSDB

:   Web-based trial selection database
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